TICKERNOMICS Sign up
Last Update: 2023-12-23 06:04:39
ABVC BIOPHARMA INC. ( ABVC ) https://www.abvcpharma.com
1.10USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-84.06%
ABVC
SPY
30.72%
-97.88%
ABVC
SPY
112.82%
-99.59%
ABVC
SPY
201.04%
ABVC
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
4.35
7.68
0.10
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.43
5.88
0.48
-88.25
0.00
-0.83
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-13566.31
-86.44
-1249.38
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.2134
-66.37
-119.78
0.81
Other Earnings and Cash Flow Stats:
ABVC BIOPHARMA INC. ( ABVC ) Net Income TTM ($MM) is -11.67
ABVC BIOPHARMA INC. ( ABVC ) Operating Income TTM ($MM) is -10.91
ABVC BIOPHARMA INC. ( ABVC ) Owners' Earnings Annual ($MM) is 0.00
ABVC BIOPHARMA INC. ( ABVC ) Current Price to Owners' Earnings ratio is 0.00
ABVC BIOPHARMA INC. ( ABVC ) EBITDA TTM ($MM) is -10.76
ABVC BIOPHARMA INC. ( ABVC ) EBITDA Margin is -1249.38%
Capital Allocation:
ABVC BIOPHARMA INC. ( ABVC ) has paid 0.00 dividends per share and bought back 28.623163 million shares in the past 12 months
ABVC BIOPHARMA INC. ( ABVC ) has increased its debt by 2.162391 million USD in the last 12 months
Capital Structure:
ABVC BIOPHARMA INC. ( ABVC ) Interest-bearing Debt ($MM) as of last quarter is 3
ABVC BIOPHARMA INC. ( ABVC ) Annual Working Capital Investments ($MM) are 0
ABVC BIOPHARMA INC. ( ABVC ) Book Value ($MM) as of last quarter is 9
ABVC BIOPHARMA INC. ( ABVC ) Debt/Capital as of last quarter is 37%
Other Balance Sheet Stats:
ABVC BIOPHARMA INC. ( ABVC ) has 0 million in cash on hand as of last quarter
ABVC BIOPHARMA INC. ( ABVC ) has 5 million of liabilities due within 12 months, and long term debt 2 as of last quarter
ABVC BIOPHARMA INC. ( ABVC ) has 3 common shares outstanding as of last quarter
ABVC BIOPHARMA INC. ( ABVC ) has 0 million USD of preferred stock value
Academic Scores:
ABVC BIOPHARMA INC. ( ABVC ) Altman Z-Score is -6.94 as of last quarter
ABVC BIOPHARMA INC. ( ABVC ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
ABVC BIOPHARMA INC. ( ABVC ) largest shareholder is Vanguard Group Inc owning 18321 shares at 0.02 ($MM) value
(an insider) shares of ABVC BIOPHARMA INC. ( ABVC ) for the amount of $ on
38.99% of ABVC BIOPHARMA INC. ( ABVC ) is held by insiders, and 2.00% is held by institutions
ABVC BIOPHARMA INC. ( ABVC ) went public on 2017-10-11
Other ABVC BIOPHARMA INC. ( ABVC ) financial metrics:
FCF:-3.84
Unlevered Free Cash Flow:0.00
EPS:-3.36
Operating Margin:-13566.31
Gross Profit Margin:-86.44
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-145.83
Beta:0.81
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ABVC BIOPHARMA INC. ( ABVC ) :
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.